Safety is predictable with NERLYNX3
MOST COMMON ADVERSE REACTIONS (≥5%) IN THE NALA TRIAL3
Safety is predictable with NERLYNX3
MOST COMMON ADVERSE REACTIONS (≥5%) IN THE NALA TRIAL3
*No Grade 4 diarrhea.26
†Renal impairment includes acute kidney injury, blood creatinine increased, renal failure, and renal impairment.
AE: adverse event.
DRUG INTERACTIONS3
IMPORTANT SAFETY INFORMATION
NERLYNX® (neratinib) tablets, for oral use
INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:
CONTRAINDICATIONS: None
WARNINGS AND PRECAUTIONS:
ADVERSE REACTIONS: The most common adverse reactions (reported in ≥5% of patients) were:
To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS:
USE IN SPECIFIC POPULATIONS:
For Full Prescribing Information, please click here.
By clicking this link, you will be leaving the NERLYNX website and will be redirected to another webpage.
This information is intended for US healthcare professionals. Please confirm you are a healthcare professional to continue.